Update on the pathogenesis of Parkinson's disease.
Parkinson's disease is a primarily sporadic occurring neurodegenerative disorder of advanced age. However, in the last few years several genes have been identified that lead to a hereditary parkinsonian disorder with autosomal dominant or autosomal recessive inheritance. This includes autosomal dominant mutations in the alpha-synuclein, ubiquitin-C-terminal hydrolase-L1 (UCH-L1) and the leucine-rich repeat kinase (LRRK)2 genes and autosomal recessively inherited mutations in Parkin, PINK1, DJ-1 and the ATP13A2 genes. By taking the biochemical function of these genes and mutations into account, three underlying pathogenetic pathways can be identified: (i) altered protein quality control, (ii) oxidative stress and mitochondrial dysfunction, and (iii) disturbed kinase activity. It remains an open question whether alterations of these pathways lead to different entities of Parkinson's disease or whether they finally converge at a point that is the common pathogenetic denominator of Parkinson's disease. Finally cell death is executed by excitotoxicity, apoptosis and autophagy and appears to be facilitated by neuroinflammatory processes.
Schulz
Jörg B
JB
Dept. of Neurodegeneration and Restorative Research, Center for Neurological Medicine, University of Göttingen, Göttingen, Germany. jschulz4@gwdg.de
D006801:Humans; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D009154:Mutation; D010300:Parkinson Disease / Q000209:etiology* / Q000235:genetics*; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D043222:Ubiquitin Thiolesterase / Q000235:genetics; D051844:alpha-Synuclein / Q000235:genetics
C482860:UCHL1 protein, human; D051844:alpha-Synuclein; C495280:LRRK2 protein, human; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D017346:Protein Serine-Threonine Kinases; D043222:Ubiquitin Thiolesterase
Neurology. 2005 Apr 26;64(8):1404-10
15851731
Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5215-20
15784737
Biochim Biophys Acta. 2003 Dec 7;1643(1-3):5-10
14654223
Lancet Neurol. 2008 Jan;7(1):97-109
18093566
N Engl J Med. 2006 Jan 26;354(4):422-3
16436781
Hum Mol Genet. 2005 Aug 1;14(15):2099-111
15961413
Neuron. 2004 Nov 18;44(4):595-600
15541308
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
12498954
Mol Cell Biol. 2004 Nov;24(22):9848-62
15509788
Neuron. 2004 Nov 18;44(4):601-7
15541309
Annu Rev Pathol. 2006;1:151-70
18039111
Science. 2001 Nov 9;294(5545):1346-9
11701929
Cell. 2002 Oct 18;111(2):209-18
12408865
Arch Neurol. 2002 Oct;59(10):1541-50
12374491
Neuropathology. 2005 Dec;25(4):304-14
16382779
Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10793-8
16818890
Trends Mol Med. 2002 May;8(5):236-40
12067634
Ann Neurol. 2005 Jan;57(1):82-91
15562510
Gene. 2007 Oct 1;400(1-2):158-65
17651920
Arch Neurol. 2004 Apr;61(4):561-6
15096406
Neuron. 2006 Nov 22;52(4):587-93
17114044
Neurology. 2007 Oct 9;69(15):1480-90
17881719
Nature. 1997 Aug 28;388(6645):839-40
9278044
Nat Cell Biol. 2000 Jul;2(7):E115-9
10878819
EMBO Rep. 2004 Feb;5(2):213-8
14749723
Hum Mol Genet. 2007 Jan 15;16(2):223-32
17200152
J Neurochem. 2008 Jul;106(2):529-40
18410502
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10433-8
11504916
Exp Neurol. 2003 Jan;179(1):38-46
12504866
N Engl J Med. 2006 Jan 26;354(4):424-5
16436782
J Pharmacol Exp Ther. 1999 Feb;288(2):421-7
9918541
Curr Opin Neurol. 1994 Aug;7(4):333-9
7952242
Nat Cell Biol. 2007 Nov;9(11):1243-52
17906618
Nat Genet. 2000 Jul;25(3):302-5
10888878